High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 10, 2003, Pages 1857-1862

  Schlitt, Axel ^b   Bickel, Christoph ^b   Thumma, Prathima ^a   Blankenberg, Stefan ^b   Rupprecht, Hans J ^b   Meyer, Juergen ^b   Jiang, Xian Cheng ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Coronary artery disease; Phospholipid transfer protein; Risk factors

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PHOSPHOLIPID TRANSFER PROTEIN; PLASMA PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TECHNIQUE;

ADULT; AGED; ANGINA PECTORIS; ANGINA, UNSTABLE; CARRIER PROTEINS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPOPROTEINS; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOLIPID TRANSFER PROTEINS; PHOSPHOLIPIDS; REFERENCE VALUES; RISK FACTORS;

EID: 0141919768     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000094433.98445.7F     Document Type: Article

References (27)

1. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res. 1985;26:842-851.
2. Tall AR, Abreu E, Shuman J. Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein. J Biol Chem. 1983;258:2174-2180.
3. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem. 1993;268:4032-4036.
4. Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem. 1993;268:23098-23105.
5. Jiang XC, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996;98:2373-2380.
6. Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer HB Jr. Plasma phospholipid transfer protein: adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem. 1997;272:27393-27400.
7. Ehnholm S, van Dijk KW, van't Hof B, van der Zee A, Olkkonen VM, Jauhiainen M, Hofker M, Havekes L, Ehnholm C. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res. 1998;39:1248-1253.
8. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, Xiao X, Tall AR. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med. 2001;7:847-852.
9. Jiang XC, Qin S, Min L, Schneider M, Tall AR, Lagrost L. Phospholipid transfer protein (PLTP) deficiency represents an anti-oxidant state in mice. Circulation 2001;104:II-232.
10. Qin S, Tall AR, Jiang XC. Phospholipid transfer protein deficiency reduces atherogenesis by inhibited LDL oxidation in LDL receptor knock out mice on western type diet. Circulation 2001;104:II-329.
11. Desrumaux C, Athias A, Bessede G, Verges B, Farnier M, Persegol L, Gambert P, Lagrost L. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol. 1999;19:266-275.
12. Murdoch SJ, Carr MC, Hokanson JE, Brunzell JD, Albers JJ. PLTP activity in premenopausal women: relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res. 2000;41:237-244.
13. Riemens SC, van Tol A, Sluiter WJ. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia. 1998;41:929-934.
14. Gordon DJ, Rifkind BM. High-density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
15. Cheung MC, Wolfbauer G, Kennedy H, Brown BG, Albers JJ. Plasma phospholipid transfer protein activity in patients with low HDL and cardiovascular disease treated with simvastatin and niacin. Biochim Biophys Acta. 2001;1537:117-124.
16. Huuskonen J, Ekstrom M, Tahvanainen E, Vainio A, Metso J, Pussinen P, Ehnholm C, Olkkonen VM, Jauhiainen M. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 2000;151:451-461.
17. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, Miller NE, Metso J, Olkkonen VM, Ehnholm C, Jauhiainen M, Hattori H. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res. 2000;41:1651-1657.
18. Karkkainen M, Oka T, Olkkonen VM, Metso J, Hattori H, Jauhiainen M, Ehnholm C. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem. 2002;277:15413-15418.
19. Barbaux SC, Blankenberg S, Rupprecht HJ, Francomme C, Bickel C, Hafner G, Nicaud V, Meyer J, Cambien F, Tiret L. Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:1668-1673.
20. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr. 1998;18:297-330.
21. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203-207.
22. Lagrost L, Athias A, Lemort N, Richard JL, Desrumaux C, Chatenet-Duchene L, Courtois M, Famier M, Jacotot B, Braschi S, Gambert P. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis. 1999;143:415-425.
23. Riemens SC, Van Tol A, Stulp BK, Dullaart RP. Influence of insulin sensitivity and the TaqIB cholesteryl ester transfer protein gene polymorphism on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities and their response to hyperinsulinemia in non-diabetic men. J Lipid Res. 1999;40:1467-1474.
24. van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, Ehnholm S, Grosveld F, van der Kamp A, de Crom R. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol. 2000;20:1082-1088.
25. Jiang XC, Tall AR, Qin S, Lin M, Schneider M, Lalanne F, Deckert V, Desrumaux C, Athias A, Witztum JL, Lagrost L. J Biol Chem. 2002;277:31850-31856.
26. Maher V, Sinfuego J, Chao P, Parekh J. Primary prevention of coronary heart disease: what has WOSCOPS told us and what questions remain? West of Scotland Coronary Prevention Study. Drugs. 1997;54:1-8.
27. Kjekshus J, Pederson TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:64C-68C.